DE69633245D1 - Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation - Google Patents

Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation

Info

Publication number
DE69633245D1
DE69633245D1 DE69633245T DE69633245T DE69633245D1 DE 69633245 D1 DE69633245 D1 DE 69633245D1 DE 69633245 T DE69633245 T DE 69633245T DE 69633245 T DE69633245 T DE 69633245T DE 69633245 D1 DE69633245 D1 DE 69633245D1
Authority
DE
Germany
Prior art keywords
fibrinogen
inhibitors
spiro compounds
blood plate
dependent blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633245T
Other languages
English (en)
Other versions
DE69633245T2 (de
Inventor
J Fisher
A Jakubowski
J Masters
T Mullaney
Michael Paal
Gerd Ruehter
J Ruterbories
M Scarborough
Theo Schotten
Wolfgang Stenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Eli Lilly and Co
Original Assignee
Millennium Pharmaceuticals Inc
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc, Eli Lilly and Co filed Critical Millennium Pharmaceuticals Inc
Publication of DE69633245D1 publication Critical patent/DE69633245D1/de
Application granted granted Critical
Publication of DE69633245T2 publication Critical patent/DE69633245T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69633245T 1995-09-29 1996-09-27 Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation Expired - Fee Related DE69633245T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US455795P 1995-09-29 1995-09-29
US4557P 1995-09-29
PCT/US1996/015703 WO1997011940A1 (en) 1995-09-29 1996-09-27 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

Publications (2)

Publication Number Publication Date
DE69633245D1 true DE69633245D1 (de) 2004-09-30
DE69633245T2 DE69633245T2 (de) 2005-09-08

Family

ID=21711385

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633245T Expired - Fee Related DE69633245T2 (de) 1995-09-29 1996-09-27 Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Country Status (10)

Country Link
US (3) US6291469B1 (de)
EP (1) EP0854869B1 (de)
JP (1) JPH11512723A (de)
AT (1) ATE274499T1 (de)
AU (1) AU713235B2 (de)
CA (1) CA2233204A1 (de)
DE (1) DE69633245T2 (de)
ES (1) ES2227612T3 (de)
NZ (1) NZ320963A (de)
WO (1) WO1997011940A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087770A4 (de) 1998-06-15 2001-11-14 Merck & Co Inc Inhibitoren der prenyl-protein transferase
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AU1244001A (en) * 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
CN1246321C (zh) * 1999-12-03 2006-03-22 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物和含其作为活性成分的药物组合物
EP1263729B1 (de) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
MXPA03008529A (es) 2001-03-19 2004-06-30 Ono Pharmaceutical Co Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo.
EP1378509A4 (de) * 2001-03-19 2009-03-25 Ono Pharmaceutical Co ARZNEIMITTEL MIT TRIAZASPIRO ç5.5]UNDECANDERIVATEN ALS WIRKSTOFF
EP1390372B1 (de) 2001-05-14 2008-07-16 F. Hoffmann-La Roche Ag 1-OXA-3,9-DIAZASPIROç5.5]UNDECAN-2-ONDERIVATE UND DEREN VERWENDUNG ALS ANTAGONISTEN DES NEUROKININREZEPTORS
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US6911452B2 (en) 2001-12-28 2005-06-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
JP2006505585A (ja) * 2002-10-18 2006-02-16 モリケム メディシンズ， インコーポレイテッド ランチビオティクスで眼乾燥症を処置する方法
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
EP1619193A4 (de) * 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
EP1776362A1 (de) * 2003-07-18 2007-04-25 Virochem Pharma Inc. Spiroverbindungen und verfahren zur modulation der aktivität des chemokinrezeptors
EP1786816A4 (de) 2003-09-10 2009-11-04 Virochem Pharma Inc Spirohydantoinverbindungen und -verfahren zur modulation von chemokin-rezeptoraktivität
WO2005047286A1 (ja) * 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
BRPI0507586A (pt) 2004-02-10 2007-07-03 Hoffmann La Roche moduladores de receptor de quimiocina ccr5
CA2565457A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1753445A4 (de) * 2004-05-06 2009-05-20 Molichem Medicines Inc Behandlung von augenerkrankungen und augenleiden mit lantibiotischen zusammensetzungen
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
US7709642B2 (en) 2004-06-25 2010-05-04 Virochem Pharma, Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
WO2006006490A1 (ja) * 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
AU2005289635A1 (en) 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
GEP20125565B (en) * 2004-11-10 2012-07-10 Incyte Corp Lactam compounds and their pharmaceutical use
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007065256A1 (en) * 2005-12-06 2007-06-14 Virochem Pharma Inc. Novel spiropiperidine compounds and methods for the modulation of chemokine receptor activity
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
EP2042503B1 (de) * 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Verbindung mit gegebenenfalls geschützter acider gruppe und anwendung davon
JP2010517966A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための１−オキサ−３−アザスピロ（４．５）デカン−２−オンおよび１−オキサ−３，８−ジアザスピロ（４．５）デカン−２−オン誘導体
TW200900060A (en) * 2007-02-01 2009-01-01 Glaxo Group Ltd Chemical compounds
CN101255161B (zh) * 2007-02-28 2011-07-20 上海药明康德新药开发有限公司 9-pg-3,9-二氮杂-2,4-二氧代-螺[5.5]十一烷的合成方法
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
AU2008233930A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
WO2009039431A2 (en) * 2007-09-21 2009-03-26 Neurogen Corporation Substituted aryl-fused spirocyclic amines
WO2009097405A2 (en) * 2008-01-30 2009-08-06 Neurogen Corporation Compounds and methods for preparing diazaspiro derivatives
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012064642A1 (en) * 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors
PT2670752E (pt) 2011-02-02 2016-06-14 Vertex Pharma Piperidinamidas pirrolopirazina-espirocíclicas como moduladores de canais iónicos
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
MX347982B (es) * 2011-03-14 2017-05-22 Vertex Pharma Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
JP5964426B2 (ja) * 2011-08-19 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 脂肪酸シンターゼ阻害剤
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
MX2014008591A (es) * 2012-01-16 2014-08-22 Vertex Pharma Piperidinamidas piranoespirociclicas como moduladores de canales de iones.
WO2014008223A2 (en) * 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
FR3000064A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9951052B2 (en) 2013-10-31 2018-04-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015096035A1 (en) * 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3134408B1 (de) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (de) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulierungen von pimavanserin
CN111533739B (zh) * 2020-05-08 2023-05-05 上海皓鸿生物医药科技有限公司 3-烷基-3,9-二氮杂螺[5,5]十一烷的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1993013101A1 (en) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
WO1994008577A1 (en) 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69327536T2 (de) 1992-10-14 2000-07-06 Merck & Co Inc Fibrinogenrezeptor-antagonisten
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
NZ262664A (en) 1993-02-22 1997-04-24 Merck & Co Inc Heterocyclic substituted derivatives, and medicaments thereof
US5441952A (en) 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
JPH09505590A (ja) 1993-11-24 1997-06-03 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 新規なイソオキサゾリンおよびイソオキサゾールフィブリノーゲン受容体拮抗剤
US5451578A (en) 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives

Also Published As

Publication number Publication date
EP0854869B1 (de) 2004-08-25
JPH11512723A (ja) 1999-11-02
US20020013325A1 (en) 2002-01-31
US6693109B2 (en) 2004-02-17
EP0854869A1 (de) 1998-07-29
US20030171373A1 (en) 2003-09-11
CA2233204A1 (en) 1997-04-03
US6291469B1 (en) 2001-09-18
AU713235B2 (en) 1999-11-25
ES2227612T3 (es) 2005-04-01
US6528534B2 (en) 2003-03-04
ATE274499T1 (de) 2004-09-15
DE69633245T2 (de) 2005-09-08
WO1997011940A1 (en) 1997-04-03
AU7382896A (en) 1997-04-17
NZ320963A (en) 1999-08-30
MX9802379A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
DE69633245D1 (de) Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
DE60005545D1 (de) Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
ATE165825T1 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
ATE354568T1 (de) Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
DE69417012T2 (de) Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase
NZ526470A (en) Pyrazole compounds useful as protein kinase inhibitors
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
EP1612204A4 (de) Hydrazon-derivate
DE69228881D1 (de) Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
DE69620165T2 (de) Piperazinone als inhibitoren von blutplattchenaggregation
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
BRPI0415015A (pt) certas lactamas espirocìclicas substituìdas e uso destas como produtos farmacêuticos
HUP0500136A2 (hu) Oxitocin antagonista hatású szubsztituált diketo-piperazinok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0415661A (pt) uso de um composto, composição farmacêutica, e, composto
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
TR200102514T2 (tr) COPD tedavisi için metod
PE20000734A1 (es) Compuestos heterociclicos derivados de furopiridina y su uso terapeutico
BR0116304A (pt) Benzoilpiridazinas
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee